Biotechnology Jobs

• Waltham, United States
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy, regulatory submissions and cross-functional matrix teams.

AI/ML

• Stevenage
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human, dose-escalation and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, benefit-risk, regulatory submissions and translational biomarker strategy across lung and head/neck cancer assets.

AI/ML

• USA - Pennsylvania - Upper Providence
• Hybrid · 2 days in office
• US$242,250 – US$403,750 pa
• Director · manages people

Accountable for end-to-end clinical development strategy for an antibody-drug conjugate asset across multiple tumour types, from first-in-human through registrational trials and launch. Acts as senior clinical representative at governance forums and leads cross-functional, matrixed teams spanning research, precision medicine, medical affairs and commercial.

• Stevenage
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late pre-candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Waltham, United States
• Hybrid
• £188,100 – £313,500 pa
• Director

Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.

NONMEM · R

• London
• Hybrid
• £119,250 – £198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within Oncology Translational Medicine's Clinical Pharmacology Modelling and Simulation group, working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Belgium-Wavre
• Hybrid
• €119,250 – €198,750 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis to small molecules, biologics and antibody drug conjugates. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.

NONMEM · R

• Durham Blackwell Street
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Waltham, United States
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with cross-functional partners in digital medicine, translational imaging and systems modelling. Based in the newly established Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML

• London
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, imaging, modelling and data science partners. Reports into the Respiratory, Immunology & Inflammation Research Unit.

AI/ML · Digital Medicine · Translational Imaging +3

• Stevenage
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, translational imaging and modelling specialists. Based in Stevenage with a planned relocation to Cambridge, UK by early 2029.

MIDD · QSP · AI/ML

• Durham, United States
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and partners with digital medicine, translational imaging, biostatistics and AI/ML teams. Reports into the Respiratory, Immunology & Inflammation Research Unit within the new Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML

• Waltham, United States
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Drafts regulatory content for FDA, EMA, CDE, PMDA and ICH submissions, and partners with digital medicine, translational imaging, modelling and data science teams to embed quantitative approaches into asset-level decisions.

MIDD · QSP · AI/ML

• London
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Sits in the Clinical Pharmacology and Quantitative Medicine organisation, partnering with digital medicine, translational imaging, modelling and data science teams, and drafting regulatory content for FDA, EMA and ICH submissions.

MIDD · QSP · AI/ML